This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Seres Therapeutics (MCRB) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Seres Therapeutics (MCRB) delivered earnings and revenue surprises of -50.00% and -84.51%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Nasdaq's Best Third Quarter in 10 Years: Best ETFs & Stocks
by Sanghamitra Saha
The tech-heavy Nasdaq index posted its best third quarter in 10 years this year.
Biotech Stock Roundup: BMY & REGN Q2 Earnings, Gilead NDA for Coronavirus Drug
by Zacks Equity Research
The biotech sector remains in focus with earnings, regulatory and other pipeline updates.
Do Options Traders Know Something About Seres Therapeutics (MCRB) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Seres Therapeutics (MCRB) stock based on the movements in the options market lately.
Earnings Preview: Seres Therapeutics (MCRB) Q2 Earnings Expected to Decline
by Zacks Equity Research
Seres Therapeutics (MCRB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Seres Therapeutics (MCRB) in Focus: Stock Moves 10.8% Higher
by Zacks Equity Research
Seres Therapeutics (MCRB) saw a big move last session, as its shares jumped nearly 11% on the day, amid huge volumes.
Implied Volatility Surging for Seres Therapeutics (MCRB) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Seres Therapeutics (MCRB) stock based on the movements in the options market lately.
Implied Volatility Surging for Seres Therapeutics (MCRB) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Seres Therapeutics (MCRB) stock based on the movements in the options market lately.
Seres Therapeutics (MCRB) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Seres Therapeutics (MCRB) delivered earnings and revenue surprises of 3.45% and 2.24%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Seres Therapeutics (MCRB) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
by Zacks Equity Research
Seres Therapeutics (MCRB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Seres Therapeutics (MCRB) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Seres Therapeutics (MCRB) delivered earnings and revenue surprises of 3.85% and 11.76%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Seres Therapeutics (MCRB) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Seres Therapeutics (MCRB) delivered earnings and revenue surprises of 11.54% and 5.16%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Seres Therapeutics, Inc. (MCRB) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Seres Therapeutics, Inc. (MCRB).
Seres Therapeutics (MCRB) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Seres Therapeutics (MCRB) delivered earnings and revenue surprises of 42.86% and 21.78%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Seres Therapeutics (MCRB) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
by Zacks Equity Research
Seres Therapeutics (MCRB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Seres Therapeutics (MCRB) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Seres Therapeutics (MCRB) delivered earnings and revenue surprises of -27.91% and -15.00%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Seres Therapeutics (MCRB) in Focus: Stock Moves 6.7% Higher
by Zacks Equity Research
Seres Therapeutics (MCRB) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Seres Therapeutics (MCRB) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Seres Therapeutics (MCRB) delivered earnings and revenue surprises of 5.26% and -61.35%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Seres Therapeutics Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Seres Therapeutics has been struggling lately, but the selling pressure may be coming to an end soon.
Seres Therapeutics (MCRB) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Seres Therapeutics (MCRB) delivered earnings and revenue surprises of 1.45% and -11.56%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Seres Therapeutics (MCRB) Catches Eye: Stock Gains 9.2%
by Zacks Equity Research
Seres Therapeutics, Inc. (MCRB) shares rose a little above 9% in the last trading session.
Seres Therapeutics' Stock Up as SER-109 Moves to Phase III
by Zacks Equity Research
Shares of Seres Therapeutics, Inc. (MCRB) went up by more than 5% on Monday, after it announced that its lead pipeline candidate, SER-109, has moved into late-stage development for the treatment of multiply recurrent C. difficile infection.
Why Seres Therapeutics (MCRB) Might Surprise This Earnings Season
by Zacks Equity Research
Seres Therapeutics (MCRB) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Seres Therapeutics (MCRB) Rises: Stock Adds 5% in Session
by Zacks Equity Research
Seres Therapeutics, Inc. (MCRB) shares rose over 5% in the last trading session.